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Background and aim: Limitations of the currently recommended stepwise treatment pathway for type 2 diabetes
mellitus (T2DM), especially the failure of monotherapies to maintain good glycemic control, have prompted use of
early, more aggressive combination therapies.
The VISION study is designed to explore the efficacy and safety of vildagliptin as an add-on to metformin therapy
compared with up-titration of metformin monotherapy in Chinese patients with T2DM.
Methods: VISION, a 24-week, phase 4, prospective, randomized, multicenter, open-label, parallel-group study, will
include 3312 Chinese T2DM patients aged ≥18 years who are inadequately controlled (6.5% >HbA1c ≤9%) by metformin
(750–1000 mg/day). Eligible patients will be randomized to receive either vildagliptin plus metformin or up-titration of
metformin monotherapy (5:1). Patients will also be subgrouped (1:1:1:1) based on their age and body mass index
(BMI): <60 years and <24 kg/m2; <60 years and ≥24 kg/m2; ≥60 years and <24 kg/m2; and ≥60 years and ≥24 kg/m2.
Conclusion: The VISION study will test the hypothesis that early use of combination therapy with vildagliptin and
metformin will provide good glycemic control and will be better tolerated than up-titration of metformin monotherapy.
The study will also correlate these benefits with age and BMI.
Keywords: VISION study, Vildagliptin, Type 2 diabetes, Study design, DPP-IV inhibitorsBackground
Type 2 diabetes mellitus, a chronic metabolic disorder of
complex pathophysiology, is prevalent worldwide [1].
According to the 2011 estimates of the World Health
Organization (WHO), there are currently approximately
346 million adults affected by diabetes globally [2]. In
China, a total diabetes prevalence of 9.7% (92.4 million
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reproduction in any medium, provided the orMetabolic Disorders Study in 2007–2008, while the
prevalence of prediabetes was estimated to be 15.5%
(148 million adults) [3]. The prevalence of diabetes was
highest among individuals aged ≥60 years and among
those with a body mass index (BMI) >30 kg/m2 [3].
Management of diabetes aims at improving glycemic
control, which is typically measured as reductions in
glycated hemoglobin (HbA1c) [4]. Current guidelines de-
fine the target for glycemic control as HbA1c <7.0% or
<6.5% [1,4]. Several classes of antihyperglycemic agents
with different mechanisms of action are currently avail-
able. Metformin and the thiazolidinediones suppress in-
sulin resistance while α-glucosidase inhibitors act within
the gastrointestinal (GI) tract to lower postprandialhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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crease β cell insulin secretion in a glucose-independent
manner. Dipeptidyl peptidase IV (DPP-IV) inhibitors
and glucagon like peptide-1 (GLP-1) analogs improve in-
sulin secretion and suppress glucagon secretion by
glucose-dependent mechanisms [5].
Current clinical practice guidelines recommend a step-
wise treatment pathway for diabetes [1]. Lifestyle modifi-
cations such as weight reduction, dietary adjustments,
and physical exercise form the first step of treatment
followed by initiation of monotherapy. Metformin is
recommended as the first-line oral antihyperglycemic
agent in most patients with T2DM by almost all clinical
practice guidelines. Along with its favorable effect on
blood glucose, metformin is associated with a low inci-
dence of weight gain and hypoglycemia, and it also
has cardioprotective properties [1,5-10]. Subsequent
stepwise intensification of metformin monotherapy is
recommended if glycemic control is inadequate [1,5,11].
In patients with persistent hyperglycemia even after the
maximum effective and/or tolerated dose of metformin is
used, the rapid addition of other antihyperglycemic agents
is recommended [11]. If glucose control remains inad-
equate, another medication should be added to the initial
therapy [1,11].
The stepwise treatment approach is, however, associ-
ated with several limitations. Lifestyle interventions are
difficult to be implements and maintain, and have failed
to achieve effective glycemic control alone [12]. Given
the limitation of monotherapies to act on the multiple
pathophysiological mechanisms involved in glucose con-
trol, they frequently fail to achieve the target glycemic
goal [1]. Failure of monotherapies is also attributed to
their inability to prevent deterioration of pancreatic β-
cell function, which is commonly observed in diabetes
[13,14]. Although monotherapies can provide initial gly-
cemic control, several clinical studies have demonstrated
failure of monotherapy to maintain long-term glycemic
control [15]. The United Kingdom Prospective Diabetes
Study (UKPDS 49), demonstrated that long-term mono-
therapy with either insulin, sulfonylureas, or metformin
could not sustain the glycemic control initially achieved
(HbA1c <7%). Approximately 50% and 75% of patients
required the addition of at least one more pharmaco-
logical agent after 3 years and 9 years of follow-up, re-
spectively [16]. A Diabetes Outcome Progression Trial
(ADOPT) compared the durability of glycemic control
in patients receiving rosiglitazone, metformin, or glyburide
as initial monotherapy [17]. All these monotherapies even-
tually failed to sustain the targeted glycemic control over
time. Furthermore, all were associated with high discon-
tinuation rates, mainly due to drug-related adverse effects
[17]. In another large observational study undertaken in
the UK, approximately 50% of patients failed to achievethe target HbA1c level of <7% during the first year with
sulfonylurea or metformin monotherapy. After 3 years of
follow-up, neither of the monotherapies was able to main-
tain the target HbA1c in >70% patients who had initially
achieved the goal during the first year [14]. Moreover,
these agents were associated with several adverse events
(AEs) such as hypoglycemia, weight gain, GI disturbances,
peripheral edema, and potential cardiovascular effects [8].
As recommended in the traditional stepwise approach,
intensification of therapy with higher doses has shown
to be successful in improving glycemic control. However,
the increased risk of AEs with dosage increases has
resulted in impaired patient compliance and subse-
quently poor glycemic control [12]. For example, metfor-
min therapy is associated with dose-dependent GI
adverse effects such as diarrhea, flatulence, and abdom-
inal discomfort, which often lead to treatment discon-
tinuation [18,19]. In the UKPDS 33 study, intensive
treatment with sulfonylureas or insulin was associated
with an increased incidence of hypoglycemia and weight
gain [20]. Moreover, the stepwise approach can also
cause a delay in switching from monotherapy to com-
bination therapy, which often leads to further deterior-
ation of glycemic control [1,15,19].
Thus, limitations of the stepwise treatment approach
and the progressive decline in pancreatic β-cell function
in diabetes warrants new treatment strategies. Early use
of more aggressive combination therapy, before respon-
siveness to monotherapy begins to decline, can be an ef-
fective approach [1,15]. This approach may provide
several advantages, including greater glycemic control
and the ability to act on different pathological mecha-
nisms involved in glucose dysregulation [1]. Additionally,
early interventions are particularly beneficial as they can
slow the onset and progression of T2DM and its associ-
ated complications [1]. Combination therapy typically
requires lower doses than those required for individual
monotherapies, which can reduce the adverse effects
associated with higher doses of monotherapy and thus
improve tolerability [15]. The EMPIRE study demon-
strated that early use of combination therapy comprising
submaximal doses of antihyperglycemic agents can im-
prove glycemic control without significantly increasing the
occurrence of adverse effects. The use of rosiglitazone, a
thiazolidinedione, as add-on therapy with submaximal
doses of metformin was shown to be non-inferior to up-
titration of metformin to its maximal effective dose in
reducing HbA1c [19]. Furthermore, add-on therapy was
better tolerated than metformin alone, with a lower inci-
dence of GI AEs [19]. However, the potential cardiovascular
effects associated with rosiglitazone has limited the clinical
use of this combination therapy [1]. Thiazolidinediones
are also associated with weight gain and thus the benefits
of their combination with metformin should be weighed
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combinations such as metformin with sulfonylureas, or
metformin with insulin has limited clinical use owing to
the associated hypoglycemia and weight gain [1,19,21].
Thus, the critical question that still remains to be answered
is: which antihyperglycemic agents can be used effectively
at early stages in the treatment of T2DM to effectively
complement metformin? [13,21].
The multiple physiological actions of the incretin hor-
mone glucagon-like peptide-1 (GLP-1), which include
sensitization of β cells, augmentation of glucose-stimulated
insulin secretion, inhibition of glucagon secretion, delayed
gastric emptying, and stimulation of insulin biosynthesis
make it a potentially useful therapeutic agent for the treat-
ment of diabetes [22]. However, as GLP-1 is rapidly de-
graded by DPP-IV enzyme, which limits its effects, the use
of DPP-IV inhibitors to prolong the half-life of the circulat-
ing endogenous peptide has proved an effective approach
to developing new therapeutic antidiabetic agents [22]. Re-
cent reviews of randomized studies of a minimum of 12
weeks’ duration have suggested that DPP-IV inhibitors are
well tolerated, with no reports of severe hypoglycemia and
weight gain in patients with T2DM [23,24].
Vildagliptin, a potent, selective, and orally active
second-generation DPP-IV inhibitor, was recently ap-
proved for the treatment of T2DM. Vildagliptin has been
shown to reduce fasting plasma glucose (FPG) and post-
prandial plasma glucose (PPG) levels and 24-hour gly-
cemic excursions, and suppress postprandial plasma
glucagon levels by inhibiting the activity of DPP-IV
enzyme to raise the levels of fasting and postprandial ac-
tive incretins [25-28]. It also improves insulin sensitivity,
augments meal/postprandial plasma insulin levels, and
enhances both α- and β-cell functions [28-31]. Improve-
ments in functioning of the islets of Langerhans in indi-
viduals with well-controlled T2DM receiving vildagliptin
under fasting conditions suggest a role beyond the en-
hancement of meal-induced GLP-1 and glucose-dependent
insulinotropic polypeptide (GIP) activity [32]. In drug-naïve
patients with mild hyperglycemia, vildagliptin reduced the
progressive deterioration of glycemic control over 2 years.
This indicates a favorable effect in preventing the deterior-
ation of β-cell function [33]. In clinical studies, vildagliptin
has been shown to improve glycemic control when admin-
istered as monotherapy or combination therapy in drug-na
ïve patients and in treatment-experienced patients [13,25].
In drug-naïve patients with T2DM, significant and progres-
sive reductions in HbA1c were seen over 12 weeks of
vildagliptin monotherapy (100 mg) [34].
The use of vildagliptin in combination with metformin
has been reported to be well tolerated, with no reports
of weight gain or severe hypoglycemia [35]. In patients
poorly controlled with insulin monotherapy, the effect-
iveness of add-on vildagliptin therapy was investigated ina 24-week, double-blind, randomized clinical trial. The
addition of vildagliptin not only improved glycemic
control but also reduced the severe hypoglycemic events
associated with insulin monotherapy [36]. Moreover,
vildagliptin has also been found to have a weight-neutral
effect, both as monotherapy and as combination therapy
in patients with T2DM [25].
These reports have raised an important question –
will a combination of vildagliptin plus metformin be
both effective in achieving glucose control and well tol-
erated? The multiple mechanisms of action of vildagliptin
in regulating glucose levels can complement the action of
metformin, which lowers plasma glucose without affecting
insulin secretion. Vildagliptin exerts its glucose-lowering
effect through an increase in glucose-dependent insulin
secretion, improving the sensitivity of both α and β cells
to glucose, as well as suppressing FPG, PPG and postpran-
dial glucagon secretion [13,25,26,37]. Several studies
have demonstrated the superior efficacy of vildagliptin/
metformin combination therapy in achieving target gly-
cemic goals in comparison with metformin monotherapy
[9,13,21,34]. The combination regimen was also safer,
with no increased risk of hypoglycemia, weight gain or
cardiovascular events [13]. Long-term vildagliptin/metfor-
min combination therapy has also been shown to have
beneficial effects on β-cell function [26]. Taken together
these findings provide a rationale for the clinical use of
vildagliptin plus metformin in patients with T2DM.
The VISION study ‒ VIldagliptin 50 mg bid as an
add-on to metformin 500 mg bid compared with met-
formin up to 1000 mg bid in Chinese patients with type
2 diabeteS Inadequately controlled on metformin 500
mg bid mONotherapy ‒ was designed to explore differ-
ences in the efficacy and safety of vildagliptin as add-on
therapy to metformin compared with up-titration of
metformin in patients with T2DM inadequately con-
trolled on metformin monotherapy. This study will
therefore address the question as to whether the com-
bination of submaximal metformin and vildagliptin will
provide equivalent glucose control and less AEs com-
pared with metformin up-titration. It also aims to
evaluate if the beneficial effects of vildagliptin/metfor-
min combination therapy can be correlated with vari-
ous factors such as obesity and patient age. The efficacy
and safety results of the VISION study will be pub-
lished in due course after its completion.
Materials and methods
Subjects
Male and female Chinese T2DM patients (WHO/IDF
criteria [38]) aged >18 years with HbA1c levels ranging
between 6.5% and 9.0% and BMI between 22 and 45 kg/m2
at visit 1 who have received metformin at a stable dose of
750–1000 mg daily for at least 12 weeks before screening
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to maintain their individual eating and exercise habits
during the study, and to follow all the study requirements.
Written informed consent will be obtained from each
patient prior to enrollment. Exclusion criteria for the study
are listed in Table 1.
Study design
The VISION study is a 24-week prospective, randomized,
multicenter, open-label, parallel-group controlled study.
The planned study design is represented in Figure 1.
Patients participating in the study will be subgrouped
(1:1:1:1) based on their BMI and age into 4 groups: (1)
<60 years and BMI <24 kg/m2; (2) <60 years of age and
BMI ≥24 kg/m2; (3) ≥60 years of age and BMI <24 kg/m2;
and (4) ≥60 years of age and BMI ≥24 kg/m2. In each
group, patients will be randomized according to the
study design. At visit 1, patients meeting the inclusion
criteria will be assigned to open-label metformin 500
mg bid for a 4-week lead-in period. At visit 2, patientsTable 1 Exclusion criteria for the VISION study
1. Pregnant or lactating women
2. Medical history of following diseases:
• Type 1 diabetes mellitus or diabetes caused by pancreatic injury or seco
• Acute complications of diabetes: ketoacidosis or non-ketotic hyperosmo
• Acute infections within 4 weeks prior to the screening (visit 1) that may
• Any obvious diabetic complications such as symptomatic autonomic ne
comorbid illnesses, and conditions that may affect blood glucose
• History of kidney disease or clinical diagnosis of renal insufficiency indic
μmol/L (≥1.4 mg/dL) in females
• History of a liver disease such as cirrhosis, hepatitis B, or hepatitis C (exc
(AST) greater than 2 times the ULN or total bilirubin greater than 2 times
• History of acute and chronic pancreatitis
• Malignant tumor in the past 5 years, including leukemia and lymphoma
• Torsades de pointes ventricular tachycardia or persistent, clinically releva
atrioventricular block (Mobitz type I and II) or third-degree atrioventricula
• Myocardial infarction, coronary artery bypass surgery or percutaneous c
• Congestive heart failure requiring medical treatment
3. Fasting plasma glucose >15 mmol/L (>270 mg/dL) at visit 1
4. Clinically significant thyroid-stimulating hormone levels outside the norm
5. Use of concomitant medications:
• Other antihyperglycemic agents besides metformin within 12 weeks of
• Long-term glucocorticoids (>7 consecutive days of treatment) within 4
• Treatment with growth hormone or similar drugs
• Treatment with class Ia, Ib, or Ic, or class III antiarrhythmics
• Treatment with any drug with known and frequent toxicity to a major o
6. Use of other investigational drugs at visit 1, or within 30 days or 5 half-liv
7. History of active substance abuse (including alcohol) within the past 2 ye
8. Potentially unreliable patients or patients who, in the opinion of the inve
ULN: upper limit of normal.will be randomized in a ratio of 5:1 to receive either
vildagliptin 50 mg bid plus metformin 500 mg bid
(Group A) or metformin 500 mg tid (Group B) for the
next 4 weeks. From visit 3 to the end of the study,
Group A patients will continue to receive the mainten-
ance dose of vildagliptin 50 mg bid plus metformin 500
mg bid, while group B patients will receive metformin
1000 mg bid.
The primary, secondary, and exploratory objectives of
the study are shown in Table 2. The study drug will be
discontinued if it shows unsatisfactory efficacy at week
12 (i.e., FPG >13.3 mmol/L [240 mg/dL]) confirmed by a
repeated measurement in the absence of any concurrent
illness. Worsening of glucose levels in the absence of
any other explainable concurrent disease or emergency
condition that can affect glucose levels, the occurrence
of AEs including GI side effects or clinically significant
changes in laboratory parameters, or an abnormality
that, in the opinion of the investigators, requires imme-
diate withdrawal of treatment, will also lead to the studyndary diabetes: Cushing syndrome or acromegaly
lar coma within the past 3 months
affect the efficacy and safety of the study
uropathy, gastroparesis, worsening hyperglycemia in the absence of any
ated by serum creatinine ≥132 μmol/L (≥1.5 mg/dL) in males, and ≥123
ept carriers) or Alanine transaminase (ALT), aspartate aminotransferase
the ULN
(except for carcinoma in situ of the skin)
nt ventricular tachycardia or ventricular fibrillation or second-degree
r block, or QTc prolongation (>500 ms)
oronary intervention, unstable angina, or stroke within the past 6 months
al range at visit 1
visit 1
weeks of visit 1
rgan system within the past 3 months
es of visit 1, whichever is longer
ars
stigator, are unsuitable for the study
Figure 1 Design of the VISION study.
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of liver enzymes (aspartate transaminase, alanine amino-
transferase and total bilirubin) without any clinical signs
that is confirmed by a repeat measurement within 3 work-
ing days, pregnancy, severe or frequent hypoglycemia (i.e.,
unexplained hypoglycemic events requiring the assistance
of another person or >3 hypoglycemic events within a
week), treatment with prohibited concomitant medica-
tions, or any other deviation from the treatment protocolTable 2 Primary, secondary, and exploratory objectives of the
1. Primary objective:
• To demonstrate that the change from baseline in HbA1c levels after 24
metformin 500 mg bid is non-inferior to high-dose metformin
2. Secondary objectives:
• To demonstrate in predefined patient subgroups [based on body mass
vildagliptin add-on therapy to metformin is non-inferior to high-dose me
• To determine the percentages of patients achieving the target HbA1c l
the predefined subgroups
• To determine the percentages of patients achieving the target HbA1c l
the predefined subgroups
• To determine the mean change from baseline to 24 weeks in fasting pl




• To determine the mean change from baseline to 24 weeks in body we
subgroups
• To determine the change from baseline to 24 weeks in β-cell function i
BMI: body mass index; HbA1c: glycated hemoglobin.will also lead to treatment discontinuation. The reason for
a patient discontinuing treatment will be recorded in the
case report form.
Treatment will also be discontinued if the patient can-
not tolerate the GI symptoms associated with a dose in-
crease at visit 2. If patients in Group B cannot tolerate
the GI symptoms at visit 3, the dose of metformin can
be decreased by one tablet (250 mg) until the GI symp-
toms improve. After that, the dose will be graduallyVISION study
weeks of treatment with vildagliptin 50 mg bid as add-on therapy to
index (BMI <24 and ≥24 kg/m2) and age (<60 and ≥60 years)] that
tformin in the change from baseline in HbA1c levels
evel of ≤6.5% in the two treatment arms of the overall population and in
evel of ≤6.5% in the two treatment arms of the overall population and in
asma glucose in the overall population and in the predefined subgroups
stprandial glucose in a subsample of 464 patients with type 2 diabetes
ight and lipid parameters in the overall population and in the predefined
n a subsample of 464 patients with type 2 diabetes mellitus
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in Group B will be at least 500 mg bid until week 12.
After week 12 (visit 4), dose adjustments of metfor-
min will not be allowed at any time. Adjustment of
the vildagliptin dose will not be allowed throughout
the study.
Patients discontinuing the study drug, including those
who do not attend the last visit, will be assessed for safety
within 30 days of receiving their last dose. If all random-
ized patients complete the 24-week, open treatment
period, the study will be considered completed. Premature
termination of the study will be notified to the institu-
tional review boards and/or ethics committees.
Study assessments
The primary efficacy assessment is the change in HbA1c
levels from baseline. Secondary efficacy assessments in-
clude changes in FPG, the percentage of patients with
HbA1c ≤6.5%, the percentage with HbA1c ≤6.5% with-
out GI side effects, and changes in 2-hour PPG levels.
Exploratory assessments include body weight, the serum
lipid profile, and β-cell function.
Safety assessments include any AEs, serious AEs, un-
explained elevations of liver enzymes, hypoglycemic
events, physical examination findings, vital signs, height
and weight, laboratory determinations (hematological
and biochemical parameters, urine analysis), electrocar-
diogram, pregnancy and reproductive ability evaluation,
appropriateness of the safety tests, and other indexes
such as a standard meal test.
Patients will be assessed at visit 1 (week −4), visit 2
(baseline), visit 3 (week 4), visit 4 (week 12), and visit 5
(week 24). Patients will be instructed to fast overnight
and not take the study drug before the visits at these
times. The schedule of assessments is provided in
Table 3. At visit 1, demographic information, the pa-
tient’s relevant medical history and history of diabetes
and its complications (including the date when diabetes
was confirmed; the presence or absence of proliferative
retinopathy, non-proliferative retinopathy, nephropathy,
neuropathy, or foot ulcers; and the dates these complica-
tions were confirmed) will be collected. Thyroid-stimulating
hormone levels will also be evaluated at this visit. As there
is no central laboratory for the study, all parameters will
be tested locally.
Data analysis
Intention-to-treat (ITT) analysis will be performed. The
full analysis set (FAS) will include all randomized pa-
tients who took the study drugs at least once and had at
least 1 primary or secondary efficacy evaluation after
baseline. For assessment of missing primary efficacy var-
iables, the last observation carried forward (LOCF) tech-
nique will be used. The per-protocol set (PPS) willinclude ITT patients completing at least 22 weeks of
treatment, and those who discontinued the study due to
a poor therapeutic response (FPG >13.3 mmol/L [240
mg/dL]) after 12 weeks of treatment, provided they have
no major protocol deviations and had a valid assessment
of HbA1c levels within 7 days after their last dose of
study drug. Any major deviation from the protocol will
be identified and documented in the analysis plan. Pa-
tients will be analyzed in the treatment group to which
they were randomly assigned for the efficacy assessment.
The safety analysis set (SAS) will include patients who
took the study drugs at least once and had at least 1
safety assessment after baseline. The safety analyses will
be according to the patients’ treatment, and will include
the description of any AEs.
The FAS set will be used as the primary population for
the primary efficacy variable, the change from baseline
in HbA1c levels at 24 weeks. The primary efficacy vari-
able will be analyzed using an analysis of covariance
(ANCOVA) model and the LOCF approach.
Non-inferiority of the study drug will be analyzed
using the null hypothesis and a unilateral alternative hy-
pothesis, which are defined as follows:
H0; δvildagliptin≥ δmetformin þ 0:3%
Ha; δvildagliptin < δmetformin þ 0:3%
where δ represents the change from baseline.
In order to control the overall type I error at alpha =
0.05, a sequential test procedure along with the Hochberg
procedure will be employed. Non-inferiority testing for the
overall population will be performed first. After achieving
non-inferiority for the overall population, non-inferiority
testing for the 4 subgroups will then be performed.
Secondary efficacy variables include percentages of pa-
tients achieving therapeutic goals at the study endpoint:
HbA1c ≤6.5%, HbA1c ≤6.5% without GI side effects, and
absolute decreases in HbA1c from baseline of ≥1%, ≥0.7%,
and ≥0.5%. In the FAS and PPS populations, the per-
centages of patients achieving the therapeutic goals will
be analyzed and compared between treatment groups
using the Chi-square test.
To assess the robustness of the results of the primary
efficacy analysis, i.e., the change from baseline in HbA1c
at 24 weeks, an ANCOVA model with LOCF will be
used for the PPS. For the primary and secondary efficacy
endpoints, subgroup analyses based on age and BMI will
be performed.
Safety analyses will include summaries of AEs, changes
from baseline in vital signs, the number of subjects with
post-baseline laboratory values that will fall outside
predetermined ranges, and the frequency and severity of
hypoglycemic events. Adverse events will be summarized
Table 3 Schedule of assessments
Visit 1 2 3 4 5a
Week −4 Baselineb 4 12 24
Screening:
Informed consent X





History of diabetes and its complications X
History/current status X X
Treatment evaluation:
Drugs dispensed X X X X
Drug count/check X X X X
Dosage records – metformin X X X X X
Dosage records – vildagliptin X X X X
Currently receiving antihyperglycemic drugs X
Concomitant medicines X X X X X
Validity assessment:
HbA1cc X X X X
Fasting plasma glucose X X X X X
Postprandial glucosed X X
Insulind X X
Body weight X X X X X
Standard meal test X X
Safety evaluation:
Physical examinations X X X
Vital signs X X X X X
Electrocardiogram examination X X
Hematology examinations X X X
Serum amylase X X X X
Standard biochemical testse,f X X X X
Liver function testsf X
Pregnancy testg X X
Routine urine test X X
Adverse events X X X X X
Study end X
aMust also be taken in case of early withdrawal.
bBaseline =1st day of study.
cDetermination of the HbA1c level with no central laboratory requires
high-performance liquid chromatography.
dOnly in the standard meal group.
eStandard biochemical examinations include, but are not limited to, the
following: fasting blood glucose, liver function, kidney function (serum
creatinine and blood urea nitrogen), and lipids (cholesterol and triglycerides).
fLiver function tests include ALT, AST, total and direct bilirubin, and
alkaline phosphatase.
gPregnancy tests specifically designed for women of childbearing potential.
HbA1c: glycated hemoglobin.
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of AEs by severity and by relationship to study drug will
also be provided.
The incidence of patients with any GI events will be com-
pared between treatment groups using Fisher’s exact test.
Sample size estimations
Non-inferiority testing will be performed on the sub-
groups of patients based on age and BMI. Assuming a
treatment group difference of 0, standard deviation of 1,
and a non-inferiority margin of 0.5, 690 patients will
provide 90% power at a 1-sided with significance level of
0.05. Allowing for a 20% dropout rate, the number of
subjects required for randomization is 690/ (1+20%) =
828 patients, yielding a total of 4 × 828 = 3312 subjects.
For the estimation of the sample size, nQuery Advisor®,
version 7.0, will be used.
Ethics
The design, implementation, and reporting of the VISION
study are strictly in compliance with the International
Conference on Harmonization (ICH) of Technical Re-
quirements for Registration of Pharmaceuticals for Hu-
man Use Guideline for Good Clinical Practice (GCP), and
the Helsinki Declaration of ethical principles [39,40].
Discussion
The inability of monotherapies to act on the multiple
pathophysiological mechanisms involved in T2DM and
to maintain good glycemic control as a result of pro-
gressive deterioration of β-cell function provide the ra-
tionale for the early use of combination therapy with
different classes of drugs [1,13]. As metformin lowers
plasma glucose levels without affecting insulin secre-
tion, the addition of an agent such as vildagliptin which
has a stimulatory action on insulin secretion is a suit-
able choice for combination therapy in patients with
T2DM [13,25,37]. Metformin has shown an incremen-
tal effect on levels of GLP-1 in obese subjects without
diabetes via mechanisms other than DPP-IV inhibition
[41,42]. An additive effect on levels of intact GLP-1 has
also been reported in patients with T2DM receiving
metformin and vildagliptin concomitantly as compared
with drug-naïve patients receiving only vildagliptin
[13], which further supports the use of this combin-
ation of drugs [41,42].
The efficacy and safety of metformin and vildagliptin
combination therapy has been evaluated in several placebo-
controlled and active-controlled trials. The addition of
vildagliptin to a stable dose of metformin monotherapy has
been shown to be effective in sustaining glycemic control
for at least 1 year, and in improving β-cell function and
reducing insulin resistance and inflammatory markers
[43-47]. A recent study of vildagliptin/low-dose
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tients with T2DM showed superior glycemic control and
favorable GI tolerability compared with high-dose met-
formin therapy. This suggests the potential of
vildagliptin/metformin combination therapy in the
management of T2DM [21]. A recent phase III study in
patients with inadequate glycemic control on low-dose
metformin (500 mg bid) demonstrated that the addition of
vildagliptin 100 mg qd to low-dose metformin 500 mg
bid resulted in a larger reduction in HbA1c as compared
with up-titration of metformin therapy to 1000 mg bid.
Moreover, the combination therapy was well tolerated
without any increase in hypoglycemic events, and fewer GI
events as compared with high-dose metformin monother-
apy. Thus, early and more aggressive therapy in T2DM is
more beneficial and can be considered in patients with
poor glycemic control with metformin monotherapy [9].
In comparison with Caucasians, Asians have higher
body fat at lower BMI levels and are thus more prone to
obesity and related disorders such as diabetes mellitus,
dyslipidemia, and hypertension at a lower BMI [48].
Consequently, in China, the BMI cut-offs for ‘over-
weight’ (24 kg/m2) and ‘obesity’ (28 kg/m2) are lower
than those of the WHO criteria, and the population aged
60 years or more is defined as ‘elderly’ [49]. The VISION
study will include Chinese patients with inadequate gly-
cemic control (HbA1c 6.5%-9.0%), despite being on met-
formin monotherapy. The study will categorize patients
into 4 subgroups according to their age and BMI. Pa-
tients in each group will be randomized to receive
vildagliptin (50 mg bid) plus metformin (500 mg bid) or
metformin (1000 mg bid) in a ratio of 5:1. As both obes-
ity and age are independent risk factors for the develop-
ment of T2DM and also influence the efficacy of any
antidiabetic therapy, the VISION study will evaluate the
efficacy and safety of the vildagliptin/metformin combin-
ation according to age and BMI in comparison with
high-dose metformin.
Conclusion
The VISION study aims to prove the efficacy and safety
of early intensive combination therapy with vildagliptin
and low-dose metformin in comparison with gradual up-
ward titration of metformin therapy in Chinese T2DM
patients who are inadequately controlled on low-dose
metformin monotherapy. This report describes the ra-
tionale for and the design of the VISION study, the effi-
cacy and safety results of which will be published when
the study is completed. The key design elements and re-
sults of the study will also be communicated to public
databases such as ClinicalTrials.gov.
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